Nuvilex (NASDAQ:PMCB) Stock Price Down 1% – Should You Sell?

Nuvilex Inc. (NASDAQ:PMCB)’s share price was down 1% during mid-day trading on Friday . The stock traded as low as $0.4855 and last traded at $0.4865. 45,370 shares traded hands during mid-day trading, a decline of 50% from the average session volume of 91,511 shares. The stock had previously closed at $0.4913.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Nuvilex Trading Down 1.0%

The firm has a fifty day simple moving average of $0.60 and a two-hundred day simple moving average of $0.69. The firm has a market cap of $5.23 million, a PE ratio of -0.16 and a beta of 0.66.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.